WATCH ON-DEMAND: Tracks 5-7keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
WATCH ON-DEMAND: Tracks 5-7
keyboard_arrow_leftSearch & Filter
search
Streams
WATCH ON-DEMAND: Tracks 5-7
search
Streams
Please DISREGARD the Listed Times Below. These ON-DEMAND Presentations Will Be Available To View 24 Hours a Day At Your Convenience for 30 Days
12:00am - 12:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Technology for Rapid Response to Pandemic Threats
- Amy Jenkins - Program Manager, DARPA Biological Technologies Office
12:00am - 12:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Emerging RNA Delivery Technologies and Targeted Delivery
- Vadim Dudkin - Senior Director & Head, RNA & Targeted Thera, Janssen R&D
12:00am - 1:00am60 mins
Track 7: Partnering
Panel Discussion: Streamlining the transition from discovery to manufacturing
- Kleem Chaudhary - Chief Business Officer, Checkmate Pharmaceuticals
- Matthias Schroff - Chief Operating Officer, Exicure
- Andrew Latham, Ph.D. - Director, BD and Licensing, Merck
12:30am - 1:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Therapy for Inherited Disorders of Glycogen Metabolism
- Paloma Giangrande - Director of Research, Moderna Therapeutics
12:30am - 1:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Precision Polymer Architectures and Molecular Conjugates to Enable Nucleic Acid and Peptide Therapeutics Against Undruggable Targets
- Craig Duvall, Ph.D. - Cornelius Vanderbilt Professor of Biomedical Engineering, Vanderbilt University
1:00am - 1:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
bioPROTACs Establish RAS as a Degradable Target and Provide Novel RAS Biology Insights
- Anthony Partridge, PhD - Senior Principal Scientist, Quantitative Biosciences, MSD International
1:00am - 1:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Genetic Reprogramming of TAMs by Engineered Exosomes Results in Potent Single Agent Anti-tumor Activity
- Sriram Sathy, Ph.D. - Vice President, Biology and Translational Medicine, Codiak Biosciences
1:00am - 1:30am30 mins
Track 7: Partnering
Dual Dialogue: Behind a successful licensing and collaboration agreement.
- Sue Dillon - CEO and Co-Founder, Aro Biotherapeutics
- C. Frank Bennett, Ph.D. - Chief Scientific Officer, Ionis Pharmaceuticals
1:30am - 2:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Precisely Engineered Stealth mRNAs for Oncolytic mRNA Immunotherapy
- Yusuf Erkul, M.D - Co-founder & President, Kernal Biologics
1:30am - 2:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Non-viral Delivery of CRISPR-Cas9 Ribonucleoproteins ex vivo and in vivo
- Krishanu Saha - Associate Professor, University of Wisconsin-Madison
1:30am - 2:30am60 mins
Track 7: Partnering
Panel Discussion: Deals that matter: Partnering with platform technologies: Trends, models and challenges.
- Padma Kodukula - SVP Business Development and Strategy, Precision Nanosystems
- Cory Sago - Head of Platform Research, Guide Therapeutics
- Michael Torres - Director of Biology, coFounder, ReCode Therapeutics
- Feroze Ujjainwalla - Director of Business Development & Licensing, Merck
- Yael Weiss - Vice President, Business Development, Ultrageynx
- Angele Maki - Vice President, Emerging Technology & Innovation, Eli Lilly and Company
2:00am - 2:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Designing Formulations to Enable a Broad Portfolio of mRNA Medicines
- Luis Brito, Ph.D. - Director, Formulation Design, Moderna Therapeutics
2:00am - 2:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Using Enzymes to Achieve Intracellular Gene Regulation Using Peptide Crosslinked DNA-surfactant Conjugates
- Jessica Rouge, PhD - Assistant Professor of Chemistry, University of Connecticut
2:30am - 3:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Considerations in mRNA Design to Generate Potent Prophylactic mRNA Vaccines
- Nicole Armbruster, Ph.D. - Scientist, CureVac AG
2:30am - 3:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Escape from the Endosome: We Need to Overcome a Billion-Year-Old Fortress!
- Steven Dowdy, Ph.D. - Professor, UCSD School of Medicine
2:30am - 3:30am60 mins
Track 7: Partnering
Platform technologies in drug development. What are the trends? What deal models are applicable. Co-development, out-licensing, other? What factors are relevant. Deal valuation, deal stage, players? What are the challenges faced? Path forward?
- Frédéric Legros - Chief Operating Officer, Dynacure
- Laszlo Kiss - Executive Director, Pfizer Ventures
- David Greenwald - VP Business Development, Deerfield
- Katherine Purdy - Senior Analyst , Research Partnerships, The Michael J Fox Foundation
3:00am - 3:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Messenger RNA Therapeutics for Treating Disease
- Christian Plank, Ph.D. - Chief Technology Officer, Ethris GmbH
3:00am - 3:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery to Extrahepatic Tissues
- Jayaprakash Nair, Ph.D. - Associate Director, Research, Alnylam Pharmaceuticals
3:30am - 4:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
The eTheRNA Immunotherapies’ Journey from Dendritic Cell Autologous Immunotherapeutics to a Novel Series of Oncology Off-the-shelf mRNA Products
- Stefaan De Koker - Non-clinical Principle Scientist and Site-Director, eTheRNA
3:30am - 4:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery of ASOs beyond the Liver
- Punit Seth, PhD - Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
3:30am - 4:00am30 mins
Track 7: Partnering
Building a Biotech: From Investment to IND and beyond
- Barry Kappel - President & CEO, Sapience Therapeutics
4:00am - 4:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA Clinical Update
- Allison August, MD - Senior Director, Clinical Development, Moderna Therapeutics
4:00am - 4:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Fatty-acid Conjugation Improves Functional Delivery of RNA therapeutics in the Eye
- Charles Allerson, Ph.D. - Vice President of Chemistry & Drug Development, DTx Pharma
4:00am - 4:30am30 mins
Track 7: Partnering
Fireside Chat: Case study of a Successful Investment Partnership
4:30am - 5:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Messenger RNA: Design and Manufacturing of a New Therapeutic Drug Class
- Anton McCaffrey, PhD - Senior Director of Emerging Science & Innovation, TriLink BioTechnologies, Inc.
4:30am - 5:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Targeted Delivery of Oligonucleotides
- Shalini Andersson, Ph.D. - Chief Scientist New Therapeutic Modalities, AstraZeneca
4:30am - 5:30am60 mins
Track 7: Partnering
Panel Discussion: The impact of technological advances in the TIDES Space
- Dmitry Samarsky, Ph.D. - Chief Technology Officer, Sirnaomics
- David Giljohann - CEO, Exicure
- Jens Bukrinski - Head of R&D, Swedish Biomimetics 3000
5:00am - 5:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Manufacturing and CMC Approaches to mRNA Therapeutics
- Christoph Kroener, Ph.D. - Head of Lead Structure and DNA Template Development for Individualized RNA Products, BioNTech AG
5:00am - 5:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Alternatives in Peptide Delivery: Nasal Glucagon for Treatment of Severe Hypoglycemia
- Kurt Van Scoik, PhD - Research Fellow, Eli Lilly and Company
5:30am - 6:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
mRNA CMC Strategies
- Don Parsons, PhD - Head, Early Technical Development, Moderna Therapeutics
5:30am - 6:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Bydureon BCise™: A Case Study for Successful Integration of Formulation and Device Development
- Leigh Dixon, Ph.D. - Principal Scientist, AstraZeneca
5:30am - 6:00am30 mins
Track 7: Partnering
Company Presentation: Arcturus Therapeutics
- Pad Chivukula - Chief Scientific Officer and COO, Arcturus Therapeutics
6:00am - 6:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Engineered Amphiphilic Peptides Enable Delivery of CRISPR-associated Nucleases to Airway Epithelial Cells
- David Guay, Ph.D. - Research Director, Feldan Therapeutics
6:00am - 6:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
Self-Injection Trends and the Platform Approach for Peptide and Oligonucleotide Delivery
- Ian Thompson - Vice President Business Development, Ypsomed AG
6:00am - 6:30am30 mins
Track 7: Partnering
Company Presentations: Triplet Therapeutics
- Nessan Bermingham - President & CEO, Triplet Therapeutics
6:30am - 7:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Delivery of Gene Therapy and Gene Editing with Polymer Nanoparticle
- Kunwoo Lee, Ph.D. - Chief Executive Officer, GenEdit
6:30am - 7:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Drug Delivery Device - Project Risk or Market Opportunity?
- Radoslaw Romanczuk, M.D. - Chief Commercial Officer, Copernicus
6:30am - 7:00am30 mins
Track 7: Partnering
Alnylam Pharmaceuticals - Session TBC
7:00am - 7:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Novel Delivery Technologies for Genome Editing
- Manmohan Singh, PhD - VP, Pharmaceutical Sciences and Delivery Technology, Beam Therapeutics
7:00am - 7:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
GI Device Development in a Few Movements
- Giovanni Traverso, Ph.D. - Assistant Professor, Dept. of Mechanical Engineering, Massachusetts Institute of Technology
7:00am - 8:00am60 mins
Track 7: Partnering
Panel discussion: Navigating Antitrust Challenges
- James Dean - Partner, Covington & Burling LLP
- Wesley Lepla - Senior Associate, Covington & Burling LLP
7:30am - 8:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Delivering RNA by Testing Thousands of Nanoparticles in vivo
- James Dahlman, Ph.D. - Assistant Professor, Biomedical Engineering, Georgia Institute of Technology and Emory Medical School
7:30am - 8:00am30 mins
Track 6: Drug Delivery Innovations and Strategies
Deep Mechanisms of Oral Delivery and Biomolecular Transport of Peptides and Other Molecules
- Randall Mrsny, Ph.D. - Professor of Epithelial Biology, University of Bath
8:00am - 8:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Genome Editing Delivery
- Kristy Wood, PhD - Senior Director, Nucleic Acid Therapeutics Development and Manufacturing, Intellia Therapeutics
8:00am - 8:30am30 mins
Track 6: Drug Delivery Innovations and Strategies
PL8177 OCD - Alignment of Receptor, Oral Formulation and Peptide for Maximal Therapeutic Ratio in IBD
- John Dodd, Ph.D. - Vice President, Preclinical Development, Palatin Technologies, Inc.
8:30am - 9:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Improving Delivery by Chemical Modification of sgRNAs/Making Conjugates of sgRNA
- Nadia Amrani, PhD - Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Medical School
9:00am - 9:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
ClinGuide, Gram-scale GMP sgRNA for CRISPR, A Continuation
- Joe Guiles, Ph.D. - Head of Development - Nucleic Acid Solution Division, Agilent Technologies, Inc.
9:30am - 10:00am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Complexities of Characterizing Guide RNAs for CRISPR Applications
- Steven Wolk, Ph.D. - Senior Director of Analytical Chemistry, Editas Medicine
10:00am - 10:30am30 mins
Track 5: mRNA Therapeutics and Genome Editing
Presentation Title TBA
- Matthew McNeill. PhD - Senior Bioinformatics Staff Scientist, Integrated DNA Technologies
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams
Choose Day
- WATCH LIVE (EST) September 15-18: Keynotes, Q&A’s, DiscussionsWATCH LIVE (EST) September 15-18: Keynotes, Q&A’s, Discussions
- WATCH ON-DEMAND: Tracks 1-4WATCH ON-DEMAND: Tracks 1-4
- WATCH ON-DEMAND: Tracks 5-7WATCH ON-DEMAND: Tracks 5-7
- WATCH ON-DEMAND: Spotlight PresentationsWATCH ON-DEMAND: Spotlight Presentations
- WATCH ON-DEMAND: Add-On Workshops #1-4WATCH ON-DEMAND: Add-On Workshops #1-4
- WATCH ON-DEMAND: Add-On Workshops #5-8WATCH ON-DEMAND: Add-On Workshops #5-8